Short answer
Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on March 6, 2026 reporting Item 8.01 (Other Events). ATM offering program expanded via Amendment No. 3 (March 6, 2026) with Piper Sandler as sales agent.
Nurix Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ATM offering program expanded via Amendment No. 3 (March 6, 2026) with Piper Sandler as sales agent
- Total program size set at $413.65M, inclusive of shares already sold under prior amendments: net new capacity is less than this figure
- Shares sold at-market prices over time, creating ongoing dilution risk for existing shareholders
- Structure uses existing automatic shelf registration (Form S-3), enabling rapid, flexible capital raises without additional SEC review delays
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nurix Therapeutics, Inc. 8-K filings
Get the next NRIX 8-K as it lands
Follow NRIX for push alerts, or ask the research agent what this filing means.